Dyne Therapeutics Announces Executive and Director Changes

Ticker: DYN · Form: 8-K · Filed: Dec 23, 2025 · CIK: 1818794

Dyne Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyDyne Therapeutics, INC. (DYN)
Form Type8-K
Filed DateDec 23, 2025
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001, $20.78, $45,000
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, executive-changes, director-changes

TL;DR

Dyne Therapeutics reshuffled execs and board members on 12/22/25.

AI Summary

Dyne Therapeutics, Inc. announced on December 22, 2025, changes in its executive and director roles. The company filed a Form 8-K detailing the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for its key executives.

Why It Matters

Changes in leadership and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence and stock performance.

Risk Assessment

Risk Level: low — This filing reports routine corporate governance changes and does not indicate any immediate financial distress or significant operational shifts.

Key Players & Entities

FAQ

What specific roles were affected by the executive and director changes?

The filing indicates the departure of certain officers and directors, the election of new directors, and changes to compensatory arrangements for certain officers, but does not specify the exact roles affected in this summary.

When was the earliest event reported in this Form 8-K?

The earliest event reported was on December 22, 2025.

What is Dyne Therapeutics, Inc.'s principal executive office address?

The principal executive offices are located at 1560 Trapelo Road, Waltham, Massachusetts 02451.

What is the Commission File Number for Dyne Therapeutics, Inc.?

The Commission File Number is 001-39509.

What is the IRS Employer Identification Number for Dyne Therapeutics, Inc.?

The IRS Employer Identification Number is 36-4883909.

Filing Stats: 741 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2025-12-23 07:35:24

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DYNE THERAPEUTICS, INC. Date: December 23, 2025 By: /s/ John G. Cox Name: John G. Cox Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing